Бевацизумаб при распространенном раке яичников: когда, зачем и почему?


Цитировать

Полный текст

Аннотация

Лечение распространенного рака яичников (РЯ) до сих пор остается непростой задачей, продолжая вызывать интерес у исследователей. Поскольку стандартная цитостатическая терапия не меняется в течение последних 20 лет, добавление таргетных препаратов к терапии 1-й линии является одним из перспективных подходов. в настоящее время наиболее изучена группа антиангиогенных препаратов, а бевацизумаб является одним из самых активно исследуемых таргетных препаратов. в данной работе рассматриваются результаты последних исследований, а также новые возможности и перспективы для назначения бевацизумаба при распространенном РЯ.

Об авторах

Александра Сергеевна Тюляндина

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

канд. мед. наук, ст. науч. сотр. отд-ния клинической фармакологии и химиотерапии

Список литературы

  1. Тюляндин С.А., Покатаев И.А., Тюляндина А.С. и др. Лечение распространенного рака яичников: итоги работы отделения клинической фармакологии и химиотерапии РОНЦ РАМН им. Н.Н.Блохина за 1993-2010 гг. М.: Вестн. РАМН, 2011; 12: 4-9.
  2. Armstrong D, Bundy B, Wenzel L et al. Phase III randomized trial of intravenous cisplatin and paclitaxel vs an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med 2006; 354: 34-43.
  3. Bansal G, Shulimovich M, Ratnarajah G et al. Clinical benefit and toxicity of continuing bevacizumab containing chemotherapies in patients with recurrent ovarian cancer. Cancer Therapy 2012; 8: 184-90.
  4. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37.
  5. Burger R.A, Brady M.F, Bookman M.A et al. The incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-83.
  6. Chan J, Brady J.M, Penson R et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin ± bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 2013; 23 (Suppl. 8). Abstr.
  7. Cohn A.L, Bekaii-Saab T, Bendell J.C et al. Clinical outcomes in bevacizumab treated patients with metastatic colorectal cancer: results from ARIES observational cohort study and confirmation of BRiTE data on BV beyond progression. J Clin Oncol 2010; 28 (Suppl. 15s). Abstr. 3596.
  8. du Bois A et al. AGO-OVAR 12: a randomized placebo - controlled gcig/engot - intergroup phase III trial of standard frontline chemotherapy ± nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013; 23 (Suppl. 8). Abstr.
  9. Ebos J, Lee C.R, Cruz-Munoz W et al. Accelerated metastasis after short - term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
  10. Ellis L.M, Hicklin D.J. VEGF-targeted therapy: mechanisms of anti - tumour activity. Nat Rev Cancer 2008; 8: 579-91.
  11. Fabi A, Russillo M, Ferretti G et al. Maintenance bevacizumab beyond first - line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor - positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 2012; 12: 1-7.
  12. Gore M, Harrias M. Chemotherapy for epithelial ovarian cancer - treatment at first diagnosis. The Lancet Oncol 2002; 3: 529-36.
  13. Gridelli C, Bennouna J, Castro J et al. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. Clinical Lung Cancer 2011; 12 (6): 407-11.
  14. Grothey A, Sugrue M.M, Purdie D.M et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-34.
  15. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
  16. Jayson G, Hicklin D, Ellis L et al. Antiangiogenic therapy - evolving view based on clinical trial results. Nat Rev Clin Oncol 2012; 14 (9): 297-303.
  17. Kassim S.K, El-Salahy E.M, Fayed S.T et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004; 37 (5): 363-9.
  18. Katsumata N, Yasuda M, Takahashi F et al. Dose - dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open - label, randomised controlled trial. Lancet 2009; 374: 1331-8.
  19. Masi G, Loupakis F, Salvatore L et al. Second - line chemotherapy with or without bevacizumab in metastatic colorectal cancer patients who progressed to a first - line treatment containing bevaizunab: Updated results of the phase III BEBYP trial by the Gruppo Oncologico Nord Ovest. JCO 2013; 31. Abstr. 3615.
  20. Mancuso M, Davis R, Norberg S et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Ivest 2006; 116 (10): 2610-21.
  21. Mannocci A, De Feo E, de Waure C et al. Use of trastuzumab in HER2- positive metastatic breast cancer beyond disease progression: a systematic review of published studies. Tumori 2010; 96: 385-91.
  22. Margolin K, Gordon M.S, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long - term safety data. J Clin Oncol 2001; 19: 851-6.
  23. Mc Cann G.A, Smith B, Backes F.J et al. Recurrent ovarian cancer: Is there a role for re - treatment with bevacizumab after an initial complete response to a bevacizumab - containing regimen? Gynecologic Oncol 2012; 127: 362-6.
  24. Neijt J.P, Engelholm S.A, Tuxen M.K et al. Exploratory phase III study of paclitaxel and cisplatin vs paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-92.
  25. Oza A.M, Perren T.J, Swart A.M et al. ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Eur J Cancer 2013; 49 (Suppl. 3): LBA6.
  26. Ozols R.F, Bundy B.N, Greer B.E et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected III stage, ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-200.
  27. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
  28. Perren T.J, Swart A.M, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-96.
  29. Pignata S, Scambia G, Lauria R et al. A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin plus paclitaxel in patients with advanced ovarian cancer: multicentre Italian trial on ovarian cancer (MITO-7): European Network of Gynecological Oncological Trial Group (ENGOT-ov-10). Gynecologic Cancer Inter Group (GCIG) trial. J Clin Oncol 2013; 31. Abstr. LBA 5501.
  30. Press J.Z, de Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA 1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
  31. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemotherapy for Platinum - Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. JCO 2014; 32 (13): 1302-8.
  32. von Minckwitz G, Schwedler K, Schmidt M et al. Final overall survival analysis of the TBP phase III study (GBG 26/BIG 3-05): capecitabine vs capecitabine trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment. Cancer Res 2010; 70 (Suppl. 24): 459s. Abstr. P6-14-05.

© ООО "Консилиум Медикум", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах